162 related articles for article (PubMed ID: 28928461)
1. Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.
Iuchi H; Sakamoto M; Matsutani D; Suzuki H; Kayama Y; Takeda N; Minamisawa S; Utsunomiya K
Sci Rep; 2017 Sep; 7(1):11906. PubMed ID: 28928461
[TBL] [Abstract][Full Text] [Related]
2. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
[TBL] [Abstract][Full Text] [Related]
3. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
Tahara A; Kondo Y; Takasu T; Tomiyama H
Biomed Pharmacother; 2018 Sep; 105():1033-1041. PubMed ID: 30021338
[TBL] [Abstract][Full Text] [Related]
4. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):423-36. PubMed ID: 22139434
[TBL] [Abstract][Full Text] [Related]
6. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
Yokono M; Takasu T; Hayashizaki Y; Mitsuoka K; Kihara R; Muramatsu Y; Miyoshi S; Tahara A; Kurosaki E; Li Q; Tomiyama H; Sasamata M; Shibasaki M; Uchiyama Y
Eur J Pharmacol; 2014 Mar; 727():66-74. PubMed ID: 24486393
[TBL] [Abstract][Full Text] [Related]
8. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
Eur J Pharmacol; 2018 Jan; 818():545-553. PubMed ID: 29154936
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice.
Tahara A
Eur J Pharmacol; 2021 Nov; 910():174486. PubMed ID: 34487707
[TBL] [Abstract][Full Text] [Related]
11. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
[TBL] [Abstract][Full Text] [Related]
12. Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.
Tahara A; Takasu T
Life Sci; 2018 Mar; 197():80-90. PubMed ID: 29425766
[TBL] [Abstract][Full Text] [Related]
13. Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
Tahara A
Eur J Pharmacol; 2021 Jun; 901():174076. PubMed ID: 33798599
[TBL] [Abstract][Full Text] [Related]
14. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharmacol Sci; 2012; 120(1):36-44. PubMed ID: 22971845
[TBL] [Abstract][Full Text] [Related]
15. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
Masuda T; Muto S; Fukuda K; Watanabe M; Ohara K; Koepsell H; Vallon V; Nagata D
Physiol Rep; 2020 Jan; 8(2):e14360. PubMed ID: 31994353
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
[TBL] [Abstract][Full Text] [Related]
17. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
[TBL] [Abstract][Full Text] [Related]
18. Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy.
Takasu T; Takakura S
Life Sci; 2019 Aug; 230():19-27. PubMed ID: 31125563
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Schwartz SL; Akinlade B; Klasen S; Kowalski D; Zhang W; Wilpshaar W
Diabetes Technol Ther; 2011 Dec; 13(12):1219-27. PubMed ID: 21854192
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Kadokura T; Zhang W; Krauwinkel W; Leeflang S; Keirns J; Taniuchi Y; Nakajo I; Smulders R
Clin Pharmacokinet; 2014 Nov; 53(11):975-88. PubMed ID: 25316572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
